Keyword: Donald Trump

Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.

The Democrats' new drug pricing bills are "flawed"—and likely to fail—unless Trump crosses the aisle. And as one analyst sees it, he just might.

J&J's CEO said this week the pharma industry needs to police itself on pricing. Days later, his company raised prices on two dozen drugs.

Pharma, payers, the Trump administration and Congress all have ideas for tackling drug prices, but the trick is making those ideas work together.

The president called advisers for a special meeting on drug prices after a new round of hikes from many industry players, Politico reports.

Pfizer, Eli Lilly, Sanofi and Johnson & Johnson chimed in on the federal government’s plan to tag pharma TV ads with drug prices.

Sen. Tammy Baldwin blasted Pfizer's plan to increase prices in January and called on the company to release details about its costs, plus more.

The government is riled up about drug prices and promising to drive them down, but a CMS report shows retail drug spending grew just 0.4% last year.

As the federal comment deadline looms, detractors are challenging the value of adding drug prices to pharma TV ads.

Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.